The hippocampus, a seahorse-shaped structure deep in the temporal lobe, is famously sensitive to interruptions in its blood supply. Within this structure, a narrow band of neurons called the CA1 region is particularly fragile. In humans, cardiac arrest and other events that briefly starve the brain of oxygen can wipe out CA1 neurons days after circulation has been restored, a phenomenon known as delayed neuronal death. Researchers have long used the gerbil as a model for this process, because transient occlusion of the two carotid arteries in these animals produces a remarkably reproducible pattern of CA1 injury that mirrors what is seen in human patients. It is precisely this model that the Korean team deployed to probe the role of SIRT3, a mitochondrial deacetylase enzyme that sits at the intersection of cellular metabolism and oxidative stress.

SIRT3 belongs to the sirtuin family of enzymes, a group of protein-modifying molecules that have attracted intense interest for their roles in aging, metabolism, and stress resistance. Unlike its cousins SIRT1 and SIRT2, which operate largely in the nucleus and cytoplasm, SIRT3 works almost exclusively inside mitochondria. There, it removes chemical acetyl groups from metabolic enzymes, fine-tuning the machinery that converts nutrients into usable energy and keeping the organelle’s antioxidant defenses primed. When SIRT3 activity falters, mitochondria tend to leak more reactive oxygen species, the chemically aggressive byproducts of respiration that can damage DNA, proteins, and membranes. Because neurons are extraordinarily dependent on mitochondrial function and comparatively poor at buffering oxidative damage, SIRT3 has emerged as a compelling candidate for explaining why some neurons die after ischemia while others survive.

To test this idea, the researchers first mapped how SIRT3 behaves in the hippocampus after a temporary ischemic insult. In sham-operated animals that underwent surgery without artery occlusion, SIRT3 immunoreactivity, a staining technique that reveals where the protein is abundant, was found predominantly in hippocampal neurons. But two days after ischemia and reperfusion, the signal dropped significantly, indicating that the ischemic episode had depleted the CA1 region of this mitochondrial guardian. This temporal pattern set the stage for the central experiment: could restoring SIRT3 levels pharmacologically change the outcome?

Enter adjudin. The compound, which has been investigated in earlier research for its effects on SIRT3 expression, was administered to gerbils undergoing the ischemia procedure. The results were striking on several fronts. Adjudin treatment pushed SIRT3 immunoreactivity in the CA1 region above the levels seen in vehicle-treated animals after ischemia and reperfusion, effectively reversing the ischemia-induced decline. More importantly, the biochemical change was accompanied by tangible protection of brain tissue and function. Animals receiving adjudin showed significantly less delayed neuronal death in the CA1 region, the very population of cells that normally succumbs in the days following the insult.

The behavioral consequences of this protection were equally notable. Ischemia in this model typically produces locomotor hyperactivity, a measurable increase in movement that reflects the functional loss of the hippocampal circuitry. Adjudin administration significantly attenuated this hyperactivity, suggesting that the preserved neurons were still doing their job. For a field where many candidate neuroprotective agents have failed to translate from tissue-level effects into functional benefits, this pairing of histological rescue with behavioral improvement is a meaningful combination, even at the preclinical stage.

Digging into the mechanisms, the team found that adjudin markedly suppressed the surge of reactive oxygen species that follows ischemia and reperfusion. At the same time, the treatment increased immunoreactivity for glutathione peroxidase, an antioxidant enzyme that neutralizes peroxides, to levels above even those observed in sham-operated animals. This dual effect, dampening the production of damaging oxidants while boosting the cellular machinery that disposes of them, is consistent with SIRT3’s known role as a regulator of mitochondrial antioxidant capacity. The data paint a coherent picture in which the ischemia-driven loss of SIRT3 leaves mitochondria defenseless, allowing oxidative stress to accumulate until neurons cross the threshold into delayed death.

The protective effects extended beyond oxidative stress into the realm of neuroinflammation. Following ischemia, microglia, the resident immune cells of the brain, activate and migrate toward damaged tissue, releasing pro-inflammatory cytokines such as interleukin-1 beta and interleukin-6. While this response is intended to clear debris and coordinate repair, excessive or prolonged activation can itself injure surrounding neurons. In the adjudin-treated animals, the researchers observed inhibited microglial activation and decreased production of both interleukin-1 beta and interleukin-6 in the hippocampus. By quieting this inflammatory storm, adjudin appears to interrupt a second wave of damage that compounds the initial oxidative insult, offering a two-pronged defense for the embattled CA1 neurons.

The authors are careful to note an important limitation of their work. Because SIRT3 deacetylase activity and SIRT3 dependence were not directly assessed in the study, the data do not establish a SIRT3-dependent mechanism. In other words, while adjudin increased SIRT3 immunoreactivity and simultaneously reduced oxidative stress, inflammation, and neuronal death, the experiments did not prove that SIRT3 is the causal link between the two. Adjudin could conceivably act through additional pathways, and the observed correlation between SIRT3 levels and neuroprotection, however suggestive, remains just that. This kind of methodological honesty is increasingly valued in preclinical neuroscience, a field that has grappled with reproducibility concerns and with the temptation to overstate mechanistic claims.

Even with that caveat, the study offers a clear roadmap for future research. If follow-up experiments using SIRT3 knockdown or pharmacological inhibition confirm that the enzyme is genuinely required for adjudin’s protective effects, the case for SIRT3 as a therapeutic target in ischemic brain injury would become substantially stronger. The broader implications are considerable: cerebral ischemia underlies not only stroke and cardiac arrest but also contributes to cognitive decline in conditions ranging from vascular dementia to Alzheimer’s disease, and mitochondrial dysfunction is a common thread running through many of them. For now, the image that emerges from this gerbil study is an intriguing one, a drug that replenishes a mitochondrial guardian just as the brain’s most fragile neurons need it most, buying them time to survive an insult that would otherwise prove fatal. Whether that image will hold up in more rigorous mechanistic tests, and ultimately in the clinic, is the question the next round of experiments must answer.

Subject of Research: Neuroprotective effects of adjudin on ischemic hippocampal injury and SIRT3 expression in a gerbil model of transient forebrain ischemia

Article Title: Adjudin attenuates ischemic hippocampal damage in gerbils in association with increased SIRT3 immunoreactivity

Article References: Hahn, K. R., Kwon, H. J., Go, H., Moon, S. M., Jung, H. Y., Kim, D. W., Kim, W., & Yoo, D. Y. (2026). Adjudin attenuates ischemic hippocampal damage in gerbils in association with increased SIRT3 immunoreactivity. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01056-9

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01056-9

Keywords: SIRT3, adjudin, cerebral ischemia, hippocampus, CA1 neurons, delayed neuronal death, reactive oxygen species, glutathione peroxidase, microglial activation, neuroinflammation, mitochondrial dysfunction, gerbil model